Cargando…
Urine Biomarkers for the Early Detection of Ovarian Cancer – Are We There Yet?
Ovarian cancer affects around 7500 women in the United Kingdom every year. Despite this, there is no effective screening strategy or standard treatment for ovarian cancer. If diagnosed during stage I, ovarian cancer has a 90% 5-year survival rate; however, there is usually a masking of symptoms whic...
Autores principales: | Grayson, Kelly, Gregory, Ebony, Khan, Ghazala, Guinn, Barbara-Ann |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393943/ https://www.ncbi.nlm.nih.gov/pubmed/30833816 http://dx.doi.org/10.1177/1179299X19830977 |
Ejemplares similares
-
Standardized urine biomarkers in assessing neonatal kidney function: are we there yet?()
por: Mak, Robert H., et al.
Publicado: (2021) -
Infrequent Expression of the Cancer-Testis Antigen, PASD1, in Ovarian Cancer
por: Khan, Ghazala, et al.
Publicado: (2015) -
Early detection of central lung cancer: are we there yet?
por: Musani, Ali I, et al.
Publicado: (2015) -
Biomarkers for SUDEP: Are We There Yet?
por: King-Stephens, David
Publicado: (2019) -
Are we there yet?
por: Wise, Jo Ann
Publicado: (2015)